Nick Makridakis           

Dr. Makridakis is interested in understanding the complex cooperative relationship between genetic and environmental contributors of multi-factorial diseases, particularly cancer.

Recent Publications:

• Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JKV. Association of missense substitution in the SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles USA. The Lancet, 354: 975-978, 1999.
• Makridakis NM, diSalle E, Reichardt JKV. Biochemical and pharmacogenetic dissection of human steroid 5alpha-reductase type II. Pharmacogenet, 10: 407-413, 2000.
• Makridakis NM, Reichardt JKV. MAPA: multiplex automated primer extension analysis: simultaneous genotyping of up to four polymorphisms. BioTechniques, 31: 1374 - 1380, 2001.
• Makridakis NM, Akalu A, Reichardt JKV. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene, 23: 7399-7405, 2004.
• Makridakis NM, Reichardt JKV. Pharmacogenetic analysis of human steroid 5alpha reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol, 34: 617-623, 2005.
• Makridakis NM, Buchanan G, Tilley W, Reichardt JKV. Androgen metabolic genes in prostate cancer predisposition and progression. Front Biosci, 10: 2892-2903, 2005.

Contact info: nmakrida@tulane.edu